Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06823713 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

Study acronym: EMERALD
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 14 to 15
    • Eligibility criteria expanded, about 50 words
    • Secondary endpoints: details revised at 2 of 3 entries
    • Publications: details revised at 3 of 4 entries
  2. Enrollment closed, study ongoing
    • Site details revised at 14 of 14 sites
    v7
  3. Site details revised at 3 of 14 sitesv6
  4. Study sites: 12 to 14
    • Study description shortened, about 10 words
    v5
  5. Study sites: 9 to 12
    • Eligibility criteria expanded, about 212 words
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 7 to 9v3
  2. Site details revised at 2 of 7 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.
Trial Details
NCT Number NCT06823713
Lead Sponsor Resolution Therapeutics Limited
Conditions
(from sponsor)		 End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases, Fibrosis and Cirrhosis of Liver, Decompensated Liver Cirrhosis, Decompensated Cirrhosis, Steatotic Liver Disease
Related terms End Stage Liver Disease, Fibrosis, Hepatic Encephalopathy, Jaundice, Liver Cirrhosis, Liver Diseases
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov